Edgewise Grants 119,250 Stock Options to New Employees
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Edgewise Therapeutics announced that on December 31, 2025, Edgewise granted inducement stock options to purchase a total of 119,250 shares of Edgewise's common stock to 4 new non-executive employees in connection with the commencement of their employment, pursuant to Edgewise's 2024 Inducement Equity Incentive Plan.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EWTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EWTX
Wall Street analysts forecast EWTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for EWTX is 38.14 USD with a low forecast of 16.00 USD and a high forecast of 51.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Analyst Rating
8 Buy
1 Hold
0 Sell
Strong Buy
Current: 28.780
Low
16.00
Averages
38.14
High
51.00
Current: 28.780
Low
16.00
Averages
38.14
High
51.00
About EWTX
Edgewise Therapeutics, Inc. is a muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The Company’s lead product candidate, sevasemten (EDG-5506), is an orally administered skeletal myosin inhibitor in late-stage clinical trials in Becker and Duchenne muscular dystrophies. Its EDG-7500 is a novel cardiac sarcomere modulator for the treatment of hypertrophic cardiomyopathy and other diseases of diastolic dysfunction, which is in Phase II clinical development. The Company is using its proprietary drug discovery platform to develop a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address a broad array of serious muscle disorders. Its platform utilizes custom-built high throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
iShares U.S. Pharmaceuticals ETF Declines 1.8% on Thursday
- ETF Underperformance: The iShares U.S. Pharmaceuticals ETF fell approximately 1.8% during Thursday afternoon trading, indicating a weak performance that may undermine investor confidence.
- Weak Component Stocks: Among the ETF's weakest performers were Omeros, down about 7%, and Edgewise Therapeutics, down approximately 6.4%, highlighting the overall pressure within the pharmaceutical sector.
- Market Volatility Impact: The overall market volatility on Thursday may have exacerbated investor concerns regarding the pharmaceutical industry, leading to capital outflows that further impacted the ETF's performance.
- Investor Sentiment Shift: As pharmaceutical stocks decline, investors may reassess their investment strategies in the sector, potentially influencing future capital flows and market dynamics.
Continue Reading
Edgewise Therapeutics CEO to Present at 44th J.P. Morgan Healthcare Conference
- Conference Presentation: Edgewise Therapeutics CEO Kevin Koch, Ph.D., will present at the 44th J.P. Morgan Healthcare Conference on January 13, 2026, where he is expected to discuss the company's latest advancements in muscle disease treatments, enhancing its visibility in the biopharmaceutical industry.
- Live Webcast: The presentation will be webcast live, allowing users to connect a few minutes prior to ensure timely access, which not only facilitates information dissemination to investors but also strengthens the company's engagement with its stakeholders.
- Product Development: Edgewise is developing Sevasemten, a first-in-class orally administered fast skeletal myosin inhibitor currently in late-stage clinical trials for Becker and Duchenne muscular dystrophies, showcasing the company's innovative potential in muscle disease therapies.
- Cardiac Disease Treatments: The company is also advancing EDG-7500 and EDG-15400 in clinical development for hypertrophic cardiomyopathy and heart failure, respectively, indicating Edgewise's strategic positioning in the cardiac treatment market to meet growing demand.
Continue Reading